Copilot
Your everyday AI companion
About 5,220,000 results
  2. People also ask
    Who is elahere used for?
    ELAHERE® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

    AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansin…

    finance.yahoo.com
    Will elahere be approved for ovarian cancer?
    By Colin Kellaher AbbVie on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its recently acquired Elahere cancer drug for certain adults with ovarian cancer.

    AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer

    marketwatch.com
    Can elahere cause ocular adverse reactions?
    ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis. Ocular adverse reactions occurred in 59% of patients with ovarian cancer treated with ELAHERE.

    AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansin…

    finance.yahoo.com
    Does AbbVie own elahere?
    Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that closed earlier this year. AbbVie reported global Elahere net revenue of $128 million in the second quarter.

    AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer

    marketwatch.com
    Feedback
  3. MarketWatch
    https://www.marketwatch.com/story/abbvie-gets-chmp...

    AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer

  4. Yahoo Finance
    https://finance.yahoo.com/news/abbvie-receives...

    AbbVie Receives Positive CHMP Opinion for Mirvetuximab …

  5. PR Newswire
    https://www.prnewswire.com/news-releases/abbvie...

    AbbVie Receives Positive CHMP Opinion for Mirvetuximab …

  6. europa.eu
    https://www.ema.europa.eu/en/medicines/human/EPAR/elahere

    Elahere | European Medicines Agency (EMA)

  7. AbbVie News Center
    https://news.abbvie.com/2024-03-22-U-…

    U.S. Food and Drug Administration (FDA) Grants Full …

    WEBMar 22, 2024 · ELAHERE is the first and only antibody-drug conjugate (ADC) approved in the U.S. for this difficult-to-treat malignancy," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global …

  8. Cancer.gov
    https://www.cancer.gov/news-events/c…

    Mirvetuximab Soravtansine-Gynx Approved for Ovarian …

    WEBApr 24, 2024 · Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation …

  9. AbbVie News Center
    https://news.abbvie.com/2023-11-30-AbbVie-to...

    AbbVie to Acquire ImmunoGen, including its Flagship Cancer

  10. AbbVie News Center
    https://news.abbvie.com/2024-06-06-Ab…

    News

    WEBJun 6, 2024 · Mirvetuximab soravtansine approved under the brand name ELAHERE® in the United States has received regulatory approval in adults with folate receptor-alpha (FRα) positive, platinum-resistant epithelial …

  11. Food and Drug Administration (.gov)
    https://www.fda.gov/drugs/resources-information...

    FDA approves mirvetuximab soravtansine-gynx (Elahere, …

  12. pharmaphorum
    https://pharmaphorum.com/news/immun…

    ImmunoGen ELAHERE wins accelerated FDA approval …

    WEB2 days ago · ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval.